DFDA

Triple Therapy (LAMA/LABA/ICS, e.g., Fluticasone furoate/Umeclidinium/Vilanterol)

Treatment for Copd

Typical Dosage: Fluticasone furoate 100 mcg/Umeclidinium 62.5 mcg/Vilanterol 25 mcg once daily

Effectiveness
70%
Safety Score
48%
Clinical Trials
10
Participants
20K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
Fluticasone furoate 100 mcg/Umeclidinium 62.5 mcg/Vilanterol 25 mcg once daily
Time to Effect
15-30 minutes (bronchodilation), weeks-months (exacerbation reduction)
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$6,600
Monitoring:$800
Side Effect Mgmt:$200
Total Annual:$7,600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$180,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$10,133
Comparison vs Umeclidinium/Vilanterol (LAMA/LABA)
Cost Difference
+$1,300/year
More expensive
QALY Difference
+0.07 QALYs
Better outcomes
Dominance
No dominance
Triple Therapy (LAMA/LABA/ICS, e.g., Fluticasone furoate/Umeclidinium/Vilanterol) Outcomes

for Copd

Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+75%
Common Side Effects
Nasopharyngitis
+18%
Headache
+15%
Oral candidiasis
+12%
Pneumonia
+8%
Upper respiratory tract infection
+10%

Sources:

nih.gov
bmj.com
a-jhr.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov